In the present study, the cytotoxic efficacy of talazoparib and APE1 inhibitor III was investigated using several distinct approaches in CD34+ MDS/CMML cells and in CD34+ or CD34− AML cells in comparison to healthy CD34+ donor cells. Here, APEX1 is linked to acute myeloid leukemia.